← Back to Search

Interferon

PEG-interferon alfa-2b for Skin Cancer

Phase 2

Waitlist Available

Research Sponsored by Eastern Cooperative Oncology Group

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up assessed every 9 weeks until suppression of plasma b-fgf level to normal, every 12 weeks until the completion of 12 months of treatment, >= 4 weeks after documented response. after off treatment, every 3 months if <2 years, and every 6 months if 2-3 years

Awards & highlights

Study Summary

RATIONALE: Peginterferon (PEG-interferon) alfa-2b may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of PEG-interferon alfa-2b in treating patients who have stage IV melanoma.

Eligible Conditions

Skin Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ assessed every 9 weeks until suppression of plasma b-fgf level to normal, every 12 weeks until the completion of 12 months of treatment, >= 4 weeks after documented response. after off treatment, every 3 months if <2 years, and every 6 months if 2-3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~assessed every 9 weeks until suppression of plasma b-fgf level to normal, every 12 weeks until the completion of 12 months of treatment, >= 4 weeks after documented response. after off treatment, every 3 months if <2 years, and every 6 months if 2-3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and assessed every 9 weeks until suppression of plasma b-fgf level to normal, every 12 weeks until the completion of 12 months of treatment, >= 4 weeks after documented response. after off treatment, every 3 months if <2 years, and every 6 months if 2-3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Plasma b-FGF Level Response

Secondary outcome measures

Non-progression Rate (Clinical Response to Peginterferon Alfa-2b)

Overall Survival

Progression Free Survival

Side effects data

From 2009 Phase 2 trial • 7 Patients • NCT00047879

50%

Fatigue

25%

Dry skin

25%

Mood alteration

25%

Seizure

25%

Metabolic, hyperglycemia

25%

Elevated AST

25%

AST

25%

Infection

25%

Elevated bilirubin

25%

Dizziness

25%

Pain, skin

25%

Fever

25%

Confusion

25%

Metabolic, ALT elevated

25%

Neurology, somnolence

25%

Rash

25%

Glucose

25%

Nausea

25%

Musculoskeletal, other leg/foot cramp

100%

80%

60%

40%

20%

Study treatment Arm

Glioblastoma Multiforme Stratum

Anaplastic Glioma Stratum

Trial Design

1Treatment groups

Experimental Treatment

Group I: PEG-interferon alfa-2bExperimental Treatment1 Intervention

Patients receive PEG-interferon alfa-2b subcutaneously (SC) once weekly. Treatment continues until basic fibroblast growth factor level is suppressed to normal or until a maximum weekly dose is reached. If there is disease progression, patients then discontinue treatment. If there is no disease progression, patients receive PEG-interferon alfa-2b SC weekly for up to 1 year in the absence of disease progression or unacceptable toxicity.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Interferon alfa

Not yet FDA approved

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Eastern Cooperative Oncology GroupLead Sponsor

268 Previous Clinical Trials

151,563 Total Patients Enrolled

National Cancer Institute (NCI)NIH

13,708 Previous Clinical Trials

40,932,697 Total Patients Enrolled

Ronald S. Go, MDStudy ChairGundersen Lutheran Center for Cancer and Blood

1 Previous Clinical Trials

8 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Recent research and studies

clinicaltrials.govStudy

PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma

2004. "PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00049530.

~1 spots leftby May 2025

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.